Chimeric Therapeutics Limited (ASX:CHM) Filings

Chimeric Therapeutics Limited

Filings

FilingDateTypeFiled with
Notification of cessation of securities - CHMOct 30, 2026FinancingASX
Notice of Annual General Meeting/Proxy FormOct 29, 2026Meeting noticeASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Ceasing to be a substantial holder for CHMOct 8, 2026Ownership change noticeASX
Notice of initial substantial holder for CHMOct 6, 2026Ownership change noticeASX
Final Director's Interest Notice - LROct 5, 2026List of directorsASX
Final Director's Interest Notice - BGOct 5, 2026List of directorsASX
Initial Director's Interest Notice - RMOct 5, 2026List of directorsASX
FY2026 Annual Report, creditor update and Board changesSep 30, 2026Annual reportASX
Application for quotation of securities - CHMSep 29, 2026FinancingASX
Application for quotation of securities - CHMSep 21, 2026FinancingASX
Application for quotation of securities - CHMSep 3, 2026FinancingASX
Appendix 4E and Preliminary Final ReportAug 31, 2026ResultsASX
Application for quotation of securities - CHMAug 27, 2026FinancingASX
Application for quotation of securities - CHMAug 20, 2026FinancingASX
CHM ceases enrolment in Phase 1 trial and Company updateAug 18, 2026Operations updateASX
Trading HaltAug 16, 2026Trading halt or suspensionASX
Application for quotation of securities - CHMAug 6, 2026FinancingASX
Quarterly Activities/Appendix 4C Cash Flow ReportJul 31, 2026Quarterly reportASX
Chimeric receives $1.62M advance on FY26 R&D tax incentiveJul 29, 2026FinancingASX
Investor PresentationJul 27, 2026Other filingsASX
CHM CDH17 Phase 1 clinical trial update - New DL 3 dataJul 15, 2026Operations updateASX
Appointment of Financial Adviser for Strategic ReviewJun 30, 2026Other filingsASX
CHM announces positive Phase 1/2 data at ASCOMay 31, 2026Other filingsASX
Consolidation/Split - CHMMar 18, 2026Other filingsASX
Chimeric receives $1.8 M advance on FY26 R&D tax incentiveMar 1, 2026FinancingASX
Half Year Report and Appendix 4D 31 December 2025Feb 27, 2026Interim reportASX
Portfolio streamlined - return of CHM CLTX to City of HopeFeb 26, 2026Operations updateASX
Funding and EGM updateFeb 24, 2026FinancingASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 27, 2026Quarterly reportASX
$8.4 M funding to drive CHM CDH17 and resignation of CMODec 22, 2025FinancingASX
Trading HaltDec 18, 2025Trading halt or suspensionASX
CDH17 granted FDA Orphan Drug Designation for Gastric CancerDec 7, 2025Operations updateASX
CHIMERIC RECEIVES $4.5M R&D TAX INCENTIVENov 23, 2025FinancingASX
75% disease control observed in CHM CDH17 trialNov 12, 2025Other filingsASX
CHM CORE NK Combination Phase 1b trial updateNov 12, 2025Operations updateASX
Pause in TradingNov 12, 2025Trading halt or suspensionASX
Response to ASX Query LetterNov 6, 2025Explanation requestASX
Additional complete responses in CHM CORE-NK Phase 1b trialOct 2, 2025Other filingsASX
Disease control and tumour shrinkage observed in CHM CDH17Sep 28, 2025Operations updateASX
Appendix 4E and Annual ReportAug 29, 2025Annual reportASX
CHM CDH17 Clinical Trial UpdateAug 3, 2025Operations updateASX
Chimeric receives $2.5 M advance on FY25 R&D tax incentiveJun 10, 2025Other filingsASX
CHM CDH17 receives FDA Fast TrackJun 4, 2025Operations updateASX
CHM CDH17 ADVANCES TO DOSE LEVEL 2May 20, 2025Operations updateASX
$6.6 million Placement to advance clinical trial pipelineMay 20, 2025FinancingASX
ADVENT-AML Phase 1B clinical trial updateMay 15, 2025Other filingsASX
Completion of Entitlement OfferApr 24, 2025FinancingASX
ProspectusMar 17, 2025Offer documentASX
Entitlement Offer to raise approximately $3.2 millionMar 17, 2025FinancingASX
Reinstatement to QuotationMar 4, 2025Trading halt or suspensionASX
Chimeric announces intention to undertake Entitlement OfferMar 4, 2025FinancingASX
Suspension from QuotationMar 2, 2025Trading halt or suspensionASX
Half Year Report and Appendix 4D 31 December 2024Feb 28, 2025Interim reportASX
$4.0m Non-Dilutionary FundingFeb 27, 2025Other filingsASX
Phase 1B CHM CORE-NK trial advances to newly diagnosed AMLDec 15, 2024Operations updateASX
Chimeric receives $4.17m R&D tax incentiveNov 27, 2024ResultsASX
AGM Presentation and CEO AppointmentNov 11, 2024Meeting outcomeASX
Reinstatement to Official QuotationOct 21, 2024Trading halt or suspensionASX
$5 million Placement to progress CHM CDH17 trialOct 21, 2024FinancingASX
AML patient achieves Complete Response in CHM CORE-NK trialOct 6, 2024Operations updateASX
Appendix 4E and Preliminary Final ReportAug 30, 2024ResultsASX
First patient dosed in Phase 1/2 trial of CHM CDH17Aug 28, 2024Other filingsASX
First patient enrolled in CHM CDH17 Phase 1/2 clinical trialJul 22, 2024Operations updateASX
Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDAJun 4, 2024Operations updateASX
Chimeric opens CHM CDH17 Phase 1/2 trialMay 22, 2024Operations updateASX
CHM CDH17 Phase 1/2 clinical trial approved for initiationMay 19, 2024Operations updateASX
Resignation of CEO and Managing DirectorMay 1, 2024Management or board changeASX
Clinical milestones for 2024 & 2023 successes highlightedMar 13, 2024Operations updateASX
Half Yearly Report and AccountsFeb 28, 2024Interim reportASX
1st patient treated in ADVENT-AML Phase 1b clinical trialFeb 7, 2024Other filingsASX
Placement of Entitlement Offer ShortfallJan 18, 2024FinancingASX
ADVENT-AML Phase 1B clinical trial open to enrolmentJan 14, 2024Operations updateASX
CHIMERIC RECEIVES $7.36M R&D TAX INCENTIVEJan 9, 2024FinancingASX
Positive in vitro data for CHM 1301 CAR NK cellsNov 22, 2023Other filingsASX
1st patient dosed in Phase 1b recurrent glioblastoma trialNov 1, 2023Operations updateASX
FDA clearance of IND for CHM 2101Oct 30, 2023Other filingsASX
Entitlement Offer to raise approximately $10 millionOct 24, 2023FinancingASX
New data for Phase 1A CLTX CAR T brain cancer clinical trialOct 22, 2023Other filingsASX
Agreement with MD Anderson for Phase 1B CHM 0201 AML studySep 12, 2023Other filingsASX
Dosing completion in Phase 1A brain cancer clinical trialAug 28, 2023Other filingsASX
Chimeric to receive A$4.4 million introduction feeAug 16, 2023Other filingsASX
Positive data - CHM 0301 next-gen armoured NK cell platformAug 14, 2023Other filingsASX
CHM secures up to A$12.6m through SPP and placementsJun 23, 2023FinancingASX
Share purchase plan completedJun 23, 2023FinancingASX
Launch of new Phase 1B Glioblastoma clinical trialJun 4, 2023Other filingsASX
SPP offer documents issued to shareholdersMay 22, 2023Offer documentASX
BOARD & MANAGEMENT COMMIT TO $1M PLACEMENT AND PROPOSED SPPMay 15, 2023FinancingASX
New CLTX CAR technology patent protection in India & IsraelApr 28, 2023Other filingsASX
Phase 1B brain cancer clinical trial approved for initiationApr 25, 2023Other filingsASX
CHM 1101 GBM Abstract Accepted for ASCO 2023 PresentationApr 3, 2023Other filingsASX
Positive pre-IND meeting with FDA for Phase 1 CAR T studyMar 20, 2023Other filingsASX
Fourth dose cohort initiated in CHM 1101 Phase 1 trialMar 2, 2023Other filingsASX
Appendix 4D and Half Year ReportFeb 28, 2023Interim reportASX
CHIMERIC RECEIVES $3.06M R&D TAX INCENTIVEFeb 14, 2023Other filingsASX
Follow up period completed for 3rd cohort in CHM 1101 trialJan 22, 2023Other filingsASX
Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trialDec 21, 2022Other filingsASX
Exclusive license agreement with CWRU for CORE-NK platformNov 20, 2022Other filingsASX
Patent received in Japan for CLTX CAR technologyAug 2, 2022Other filingsASX
Licenses viral vector technology from Penn for CDH17Jun 28, 2022Other filingsASX
A$30 million Equity Placement Agreement with L1 CapitalJun 9, 2022FinancingASX
Strategic manufacturing partnership with WuXi ATUApr 12, 2022Other filingsASX
Security Class Reinstatement to Quotation CHMOMar 27, 2022Trading halt or suspensionASX
CDH17 CAR T PRECLINICAL DATA FEATURED IN NATURE CANCERMar 23, 2022Other filingsASX
Completion of retail component of Entitlement OfferMar 22, 2022FinancingASX
Security Class Suspension from Quotation CHMOMar 20, 2022Trading halt or suspensionASX
Final Results in Phase 1 Trial of CORE NK PlatformMar 6, 2022Other filingsASX
CHIMERIC PARTNERS WITH BE THE MATCH BIOTHERAPIESMar 4, 2022Other filingsASX
Successful completion of Institutional Entitlement OfferFeb 22, 2022FinancingASX
Entitlement Offer to raise approximately $18.1 millionFeb 21, 2022FinancingASX
Encouraging data from 2nd dose cohort in CLTX CAR T trialFeb 7, 2022Other filingsASX
Sponsored Research Agreement with University of PennsylvaniaJan 31, 2022Other filingsASX
Chimeric receives US patent covering CLTX CAR technologyJan 26, 2022Other filingsASX
Transformative Portfolio Expansion PresentationNov 30, 2021Other filingsASX
CLTX CAR T data shows regional control of tumour recurrenceNov 21, 2021Other filingsASX
CLTX CAR T PRESENTS POSITIVE INITIAL PHASE 1 CLINICAL DATANov 14, 2021Other filingsASX
FIRST MILESTONE ON PATH TO CDH17 CAR T CLINICAL TRIALOct 21, 2021Other filingsASX
European patent granted for CLTX technology used in CHM 1101Sep 23, 2021Other filingsASX
Partnership with OncoBay Clinical to advance CHM 1101Sep 2, 2021Other filingsASX
Preliminary Final ReportAug 31, 2021ResultsASX
Chimeric Appoints Jennifer Chow as CEO & MDAug 30, 2021Other filingsASX
IND clearance received from US FDA for CHM 1101Aug 19, 2021Other filingsASX
Chimeric licenses novel solid tumor CAR T therapy from PennJul 27, 2021Other filingsASX
Second Dose Cohort Initiated in CLTX CAR T Phase 1 TrialMay 23, 2021Other filingsASX
Appendix 4C - quarterlyApr 23, 2021Quarterly reportASX
Successful Completion of First Patient Cohort Phase 1 TrialApr 21, 2021Other filingsASX
Successful Completion of Dosing in First Patient CohortMar 17, 2021Other filingsASX